A new medicine, TP-317, for Ulcerative Colitis
Official title: Development of TP-317 in Ulcerative Colitis
Funded at Thetis Pharmaceuticals, LLC · NIH-11056022 · Data updated 2026-11-12
This research focuses on creating an oral medicine called TP-317 to help people with ulcerative colitis manage their symptoms and stay in remission.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thetis Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Deep River, United States) |
| Project start | September 18, 2017 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $999,696 |
| NIH project number | 5R44DK116460-06 |
| Project ID | NIH-11056022 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with ulcerative colitis who are looking for new oral treatment options to manage their chronic inflammation and achieve remission may be interested in this research.
✕Less likely to help
Patients without ulcerative colitis or those whose condition is not related to the inflammatory pathways targeted by this medicine may not receive benefit.
What this research studies
Ulcerative colitis is a long-lasting condition causing inflammation and sores in the colon and rectum, affecting many people in the United States. It's believed to happen when the body's immune system overreacts to gut bacteria, leading to ongoing inflammation. This new medicine, TP-317, is designed to mimic natural body compounds that help resolve inflammation. The goal is to offer an effective oral treatment that can both calm flare-ups and prevent them from returning.
Why it matters
Potential benefit: If successful, this medicine could provide a new, stable, and easy-to-take oral treatment option for patients living with ulcerative colitis.
How similar studies have gone: Previous studies in animal models of ulcerative colitis have shown that the active component of TP-317, Resolvin E1, is effective, and prior grant funding successfully completed initial drug development steps.
Where this research is happening
-
Thetis Pharmaceuticals, LLC
Deep River, United States Active
Researchers
- Principal investigator: Parkinson, John — Thetis Pharmaceuticals, LLC
- Study coordinator: Parkinson, John
Related research
Other NIH-funded projects on the same topics.
-
Outpatient pathway for severe ulcerative colitis in the right care setting
This study tests a safe, outpatient approach using an oral therapy and remote monitoring for people with acute severe ulcerative colitis to avoid hospitalization.
-
Fh15-based therapy to calm inflammation in sepsis and ulcerative colitis
A research project tests a molecule from a parasitic organism (Fh15) to reduce harmful inflammation in adults with sepsis or ulcerative colitis.
-
IMYX-3 treatment for ulcerative colitis
A new therapy approach called IMYX-3 aims to help adults with moderate to severe ulcerative colitis who have not responded well to current treatments.
-
Autoantibodies and ulcerative colitis: how avb6 antibodies may drive disease
This NIH grant aims to understand how antibodies against a gut cell protein (αvβ6) may actively contribute to ulcerative colitis and what that means for future treatments.
-
Selenium supplementation to help moderate-severe ulcerative colitis flare-ups
This grant tests whether giving selenium can help people with moderate to severe ulcerative colitis reduce flares and improve symptoms.
-
Development of TP-317 for Ulcerative Colitis
A new therapy approach for ulcerative colitis aims to repair the intestinal lining and restore immune balance in people with UC, addressing a need for patients who don’t fully respond to current treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.